Cargando…

Evaluation of the novel USPIO GEH121333 for MR imaging of cancer immune responses

Tumor-associated macrophages (TAM) maintain a chronic inflammation in cancers, which is associated with tumor aggressiveness and poor prognosis. The purpose of this study was to: (1) evaluate the pharmacokinetics and tolerability of the novel ultrasmall superparamagnetic iron oxide nanoparticle (USP...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Qiaoyun, Pisani, Laura J, Lee, Yauk K, Messing, Solomon, Ansari, Celina, Bhaumik, Srabani, Lowery, Lisa, Lee, Brian D, Meyer, Dan E, Daldrup-Link, Heike E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3662997/
https://www.ncbi.nlm.nih.gov/pubmed/23606432
http://dx.doi.org/10.1002/cmmi.1526
_version_ 1782270915984228352
author Shi, Qiaoyun
Pisani, Laura J
Lee, Yauk K
Messing, Solomon
Ansari, Celina
Bhaumik, Srabani
Lowery, Lisa
Lee, Brian D
Meyer, Dan E
Daldrup-Link, Heike E
author_facet Shi, Qiaoyun
Pisani, Laura J
Lee, Yauk K
Messing, Solomon
Ansari, Celina
Bhaumik, Srabani
Lowery, Lisa
Lee, Brian D
Meyer, Dan E
Daldrup-Link, Heike E
author_sort Shi, Qiaoyun
collection PubMed
description Tumor-associated macrophages (TAM) maintain a chronic inflammation in cancers, which is associated with tumor aggressiveness and poor prognosis. The purpose of this study was to: (1) evaluate the pharmacokinetics and tolerability of the novel ultrasmall superparamagnetic iron oxide nanoparticle (USPIO) compound GEH121333; (2) assess whether GEH121333 can serve as a MR imaging biomarker for TAM; and (3) compare tumor MR enhancement profiles between GEH121333 and ferumoxytol. Blood half-lives of GEH121333 and ferumoxytol were measured by relaxometry (n = 4 each). Tolerance was assessed in healthy rats injected with high dose GEH121333, vehicle or saline (n = 4 each). Animals were monitored for 7 days regarding body weight, complete blood counts and serum chemistry, followed by histological evaluation of visceral organs. MR imaging was performed on mice harboring MMTV-PyMT-derived breast adenocarcinomas using a 7 T scanner before and up to 72 h post-injection (p.i.) of GEH121333 (n = 10) or ferumoxytol (n = 9). Tumor R(1), R(2)* relaxation rates were compared between different experimental groups and time points, using a linear mixed effects model with a random effect for each animal. MR data were correlated with histopathology. GEH121333 showed a longer circulation half-life than ferumoxytol. Intravenous GEH121333 did not produce significant adverse effects in rats. All tumors demonstrated significant enhancement on T(1), T(2) and T(2)*-weighted images at 1, 24, 48 and 72 h p.i. GEH121333 generated stronger tumor T(2)* enhancement than ferumoxytol. Histological analysis verified intracellular compartmentalization of GEH121333 by TAM at 24, 48 and 72 h p.i. MR imaging with GEH121333 nanoparticles represents a novel biomarker for TAM assessment. This new USPIO MR contrast agent provides a longer blood half-life and better TAM enhancement compared with the iron supplement ferumoxytol. Copyright © 2013 John Wiley & Sons, Ltd. Supporting information may be found in the online version of this paper
format Online
Article
Text
id pubmed-3662997
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-36629972013-05-24 Evaluation of the novel USPIO GEH121333 for MR imaging of cancer immune responses Shi, Qiaoyun Pisani, Laura J Lee, Yauk K Messing, Solomon Ansari, Celina Bhaumik, Srabani Lowery, Lisa Lee, Brian D Meyer, Dan E Daldrup-Link, Heike E Contrast Media Mol Imaging Full Papers Tumor-associated macrophages (TAM) maintain a chronic inflammation in cancers, which is associated with tumor aggressiveness and poor prognosis. The purpose of this study was to: (1) evaluate the pharmacokinetics and tolerability of the novel ultrasmall superparamagnetic iron oxide nanoparticle (USPIO) compound GEH121333; (2) assess whether GEH121333 can serve as a MR imaging biomarker for TAM; and (3) compare tumor MR enhancement profiles between GEH121333 and ferumoxytol. Blood half-lives of GEH121333 and ferumoxytol were measured by relaxometry (n = 4 each). Tolerance was assessed in healthy rats injected with high dose GEH121333, vehicle or saline (n = 4 each). Animals were monitored for 7 days regarding body weight, complete blood counts and serum chemistry, followed by histological evaluation of visceral organs. MR imaging was performed on mice harboring MMTV-PyMT-derived breast adenocarcinomas using a 7 T scanner before and up to 72 h post-injection (p.i.) of GEH121333 (n = 10) or ferumoxytol (n = 9). Tumor R(1), R(2)* relaxation rates were compared between different experimental groups and time points, using a linear mixed effects model with a random effect for each animal. MR data were correlated with histopathology. GEH121333 showed a longer circulation half-life than ferumoxytol. Intravenous GEH121333 did not produce significant adverse effects in rats. All tumors demonstrated significant enhancement on T(1), T(2) and T(2)*-weighted images at 1, 24, 48 and 72 h p.i. GEH121333 generated stronger tumor T(2)* enhancement than ferumoxytol. Histological analysis verified intracellular compartmentalization of GEH121333 by TAM at 24, 48 and 72 h p.i. MR imaging with GEH121333 nanoparticles represents a novel biomarker for TAM assessment. This new USPIO MR contrast agent provides a longer blood half-life and better TAM enhancement compared with the iron supplement ferumoxytol. Copyright © 2013 John Wiley & Sons, Ltd. Supporting information may be found in the online version of this paper Blackwell Publishing Ltd 2013-05 2013-03-13 /pmc/articles/PMC3662997/ /pubmed/23606432 http://dx.doi.org/10.1002/cmmi.1526 Text en Copyright © 2013 John Wiley & Sons, Ltd. http://creativecommons.org/licenses/by/2.5/ Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.
spellingShingle Full Papers
Shi, Qiaoyun
Pisani, Laura J
Lee, Yauk K
Messing, Solomon
Ansari, Celina
Bhaumik, Srabani
Lowery, Lisa
Lee, Brian D
Meyer, Dan E
Daldrup-Link, Heike E
Evaluation of the novel USPIO GEH121333 for MR imaging of cancer immune responses
title Evaluation of the novel USPIO GEH121333 for MR imaging of cancer immune responses
title_full Evaluation of the novel USPIO GEH121333 for MR imaging of cancer immune responses
title_fullStr Evaluation of the novel USPIO GEH121333 for MR imaging of cancer immune responses
title_full_unstemmed Evaluation of the novel USPIO GEH121333 for MR imaging of cancer immune responses
title_short Evaluation of the novel USPIO GEH121333 for MR imaging of cancer immune responses
title_sort evaluation of the novel uspio geh121333 for mr imaging of cancer immune responses
topic Full Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3662997/
https://www.ncbi.nlm.nih.gov/pubmed/23606432
http://dx.doi.org/10.1002/cmmi.1526
work_keys_str_mv AT shiqiaoyun evaluationofthenoveluspiogeh121333formrimagingofcancerimmuneresponses
AT pisanilauraj evaluationofthenoveluspiogeh121333formrimagingofcancerimmuneresponses
AT leeyaukk evaluationofthenoveluspiogeh121333formrimagingofcancerimmuneresponses
AT messingsolomon evaluationofthenoveluspiogeh121333formrimagingofcancerimmuneresponses
AT ansaricelina evaluationofthenoveluspiogeh121333formrimagingofcancerimmuneresponses
AT bhaumiksrabani evaluationofthenoveluspiogeh121333formrimagingofcancerimmuneresponses
AT lowerylisa evaluationofthenoveluspiogeh121333formrimagingofcancerimmuneresponses
AT leebriand evaluationofthenoveluspiogeh121333formrimagingofcancerimmuneresponses
AT meyerdane evaluationofthenoveluspiogeh121333formrimagingofcancerimmuneresponses
AT daldruplinkheikee evaluationofthenoveluspiogeh121333formrimagingofcancerimmuneresponses